Clinical, regulatory, and commercial milestone fees may reach $110 million.
Endo Pharmaceuticals will pay Bioniche Life Sciences an up-front cash fee of $20 million for exclusive rights to the latter’s Phase III bladder cancer treatment, Urocidin. The agreement covers development and marketing in the U.S. with an option for global rights.
Bioniche has the potential to receive up to $110 million in additional payments linked to the achievement of future clinical, regulatory, and commercial milestones for Urocidin. In addition, Bioniche will manufacture the product and receive a transfer price for supply.
“In August Endo plans to launch Valstar™ for the treatment of bladder cancer,” says David Holveck, president and CEO of Endo. “If successful in clinical development, Urocidin has the potential to extend and enhance our recent therapeutic expansion and strengthen the Valstar franchise.”
Urocidin is a formulation of mycobacterial cell wall-DNA complex (MCC), designed for the treatment of nonmuscle-invasive bladder cancer. It is an intravesical infusion therapy, administered via transurethral catheter into the bladder.
